Skip to main content

Roberts Eiry's Form 4 filing

Neurocrine Biosciences Inc (NBIX) · filed Dec 14, 2023

Accession no.
0001209191-23-058683
Filed
Dec 14, 2023
Trade date
Dec 12, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.68M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Roberts EiryCIK 0001727606Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 12, 2023Common StockMOption exerciseAcquired+6,978$81.05+$565,566.936,499Direct
Dec 12, 2023Common StockSSaleDisposed−6,978$120.30−$839,453.429,521Direct
Dec 12, 2023Common StockMOption exerciseAcquired+6,947$81.05+$563,054.3536,468Direct
Dec 12, 2023Common StockSSaleDisposed−6,947$120.31−$835,793.5729,521Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 12, 2023Common StockMOption exerciseDisposed−6,978$81.05−$565,566.946,387Direct
Dec 12, 2023Common StockMOption exerciseDisposed−6,947$81.05−$563,054.3539,440Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)